No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
NTLA250117C50000
- 0.20
- 0.000.00%
15min DelayClose Jan 10 16:00 ET
0.00High0.00Low
0.20Open0.20Pre Close0 Volume276 Open Interest50.00Strike Price0.00Turnover625.88%IV392.16%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type0.0705Delta0.0158Gamma51.00Leverage Ratio-0.0795Theta0.0001Rho3.60Eff Leverage0.0018Vega
Intraday
- 5D
- Daily
News
Peering Into Intellia Therapeutics's Recent Short Interest
Intellia Therapeutics Shares Are Trading Lower After the Company Announced a Strategic Reorganization to Prioritize Late-stage Programs NTLA-2002 and Nexiguran Ziclumeran.
Why Is Intellia Therapeutics Stock Trading Lower On Friday?
Gene Editing Stocks Drop as Intellia Announces Layoffs
BMO Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $50
Intellia Therapeutics Is Maintained at Overweight by Wells Fargo